(1-苯基吡咯烷-3-基)甲醇 | 99858-80-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (1-苯基吡咯烷-3-基)甲醇
• 中文别名: (1-苯吡咯烷-3-基)甲醇
• 英文名称: (1-Phenylpyrrolidin-3-yl)methanol
• CAS: 99858-80-7
• 化学式: C₁₁H₁₅NO
• mdl: MFCD08059754
• 分子量: 177.24
• InChiKey: GJFYMULJMJYQAD-UHFFFAOYSA-N

物化性质

• 熔点：
  54-55 °C
• 沸点：
  130-135 °C(Press: 0.05 Torr)
• 密度：
  1.090±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• WGK Germany：
  3

文献信息

• [EN] TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF<br/>[FR] INHIBITEURS DE LA KINASE TRKA, COMPOSITIONS EN CONTENANT ET MÉTHODES ASSOCIÉES
  申请人：MERCK SHARP & DOHME

  公开号：WO2013009582A1

  公开（公告）日：2013-01-17

  The present invention is directed to compounds of formula I and la: which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

  本发明涉及式I和la化合物，它们是原肌球蛋白相关激酶（Trk）家族蛋白激酶抑制剂，因此可用于治疗疼痛、炎症、癌症、再狭窄、动脉粥样硬化、银屑病、血栓形成、与脱髓鞘或髓鞘形成障碍相关的疾病、紊乱、损伤或功能障碍，或与神经生长因子（NGF）受体TrkA异常活性相关的疾病或紊乱。
• TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
  申请人：Hanney Barbara

  公开号：US20140155413A1

  公开（公告）日：2014-06-05

  The present invention is directed to compounds of formula I and 1a: which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

  本发明涉及公式I和1a的化合物，它们是肌动蛋白相关激酶（Trk）家族蛋白激酶抑制剂，因此在治疗疼痛、炎症、癌症、再狭窄、动脉粥样硬化、银屑病、血栓形成、与失髓鞘或脱髓鞘有关的疾病、紊乱、损伤或功能障碍，或与神经生长因子（NGF）受体TrkA的异常活动有关的疾病或紊乱的治疗中有用。
• CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD
  申请人：Ebel Heiner

  公开号：US20120053164A1

  公开（公告）日：2012-03-01

  The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. Formula (I), wherein A is selected from among a single bond, ═CH—, —CH 2 —, —O—, —S—, and —NH—; wherein n is 1, 2 or 3; wherein Z is C or N, the other variables are as defined in the claims, as well as in form of their acid addition salts with pharmacologically acceptable acids.
• PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS
  申请人：EBEL Heiner

  公开号：US20140336374A1

  公开（公告）日：2014-11-13

  The present invention relates to a process for the production of novel antagonists for CCR2 (CC chemokine receptor 2) and intermediates thereof.
• US8835440B2
  申请人：——

  公开号：US8835440B2

  公开（公告）日：2014-09-16